Brought to you by 
Theratechnologies gets exclusive rights to sell TaiMed's HIV therapy in the US and Canada; deal ends
03 May 2022
Executive Summary
Under a 12-year deal, TaiMed Biologics Inc. licensed Theratechnologies Inc. exclusive rights to market and distribute the HIV candidate ibalizumab in the US and in Canada.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Theratechnologies gets exclusive rights to sell TaiMed's HIV therapy in the US and Canada; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice